Bayer seeks wider use for eye drug Eylea in Europe
FRANKFURT Nov 7 (Reuters) - German drugmaker Bayer said it filed for marketing approval in Europe for the use of eye drug Eylea as a treatment of diabetic macular oedema.
Bayer has said it expects Eylea, also known as VEGF Trap-Eye, to generate more than 1 billion euros ($1.35 billion) in peak annual sales.
The injection, which Bayer is co-developing with Regeneron , is already approved for other eye diseases.
- Carnage at U.N. school as Israel pounds Gaza refugee camp |
- Moscow fights back after sanctions; battle rages near Ukraine crash site
- U.S. economy bounces back in second quarter
- EU and U.S. announce new sanctions on Russia over Ukraine |
- Obama says strains over Ukraine not leading to new Cold War with Russia